‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
The jab has given hope to patients after a trial found it increased the survival of more than half of participants with pancreatic cancer.
Researchers described the findings as 'remarkable' and have already started testing the efficiency of the jab among a larger group of pancreatic and bowel cancer patients.
The jab uses a new type of immunotherapy. It's designed to improve vaccine delivery to the lymph nodes, which act as filters for foreign substances in the body including cancer cells and infections.
Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS, which plays a key role in tumour growth, and scientists developed the jab to recognise and attack KRAS-mutant cancer cells.
The study, which has been published in the journal Nature Medicine, tested the jab on 20 patients with pancreatic cancer and five patients with bowel cancer.
When participants were followed up after 20 months, 68 per cent had developed strong immune responses specific to mutant KRAS tumour proteins.
Participants who had the strongest immune responses lived longer and stayed cancer-free for longer than those with weaker responses.
Researchers found patients survived about two years and five months after receiving that vaccine.
In comparison, just three in 10 people diagnosed with pancreatic cancer survive for a year.
Pancreatic cancer has some of the poorest survival rates due to late detection. It doesn't usually cause symptoms in the early stages, and as it grows, it can cause tummy pain, yellowing of the skin, unexplained weight loss and changes in stools.
Once they do receive a diagnosis, many patients see their cancer returning even after treatments such as radiotherapy and chemotherapy.
But the trial showed the jab could help prevent the cancer from returning for more than 15 months.
Unlike other cancer jabs which are personalised to individual patients, this vaccine, ELI-002 2P, has a single version which can be given to all patients.
This 'off-the-shelf' version means that it can be manufactured in bulk and given more rapidly.
Dr Dani Edmunds, research information manager at Cancer Research UK, said: 'Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat.
'Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer.
'The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment.
'These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination.
'Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine.
'More research is needed to understand why some people benefit from the vaccine while others don't, so that we can make sure we're beating cancer for everyone.'
However, Professor Richard Sullivan, director of the Centre for Conflict and Health Research at King's College London, has suggested the study doesn't prove the vaccine is ready for use.
'There is some interesting science in this study, but this is a long way from proving any sort of clinical utility,' he said.
'They mix colorectal cancers with pancreatic cancers – two widely different cancers with very different prognosis, even if the latter is surgically resected. The former has very good prognosis even with late stage disease whereas the latter is poor even if early-stage, and resected.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
27 minutes ago
- The Independent
8 best hypochlorous acid sprays to cleanse and soothe, tested by a beauty expert
Want to give your skincare routine a boost? The best hypochlorous acid sprays offer multifunctional benefits, from calming inflammation to minimising breakouts. The versatile mists lend a hand when it comes to banishing germs and bacteria. Originally used in medical settings, skin expert Dr Lauren Jamieson explains that they 'can be used for wound care, skincare, skin cleansing before procedures and general disinfection.' But while the medical applications of hypochlorous acid (HOCl) long predate its popularity in the world of beauty, the industry is catching up. Brands like Mario Badescu Tower 28, and Kanzen have all launched hypochlorous acid mists, combining the acid with other skin-loving ingredients. The claim is that the antibacterial properties in the acid can stop breakouts before they start, and ease skin conditions like eczema and rosacea. With so many brands making formulas – and as claims about the benefits of hypochlorous acid get more and more outlandish – it can be hard to work out which of these sprays actually lives up to its marketing. As more and more makeup brands jump on the bandwagon, I went to work separating the good formulas from the bad. Scroll on for my top picks, with suggestions for every skin type and budget. How I tested For several months, I tested the following hypochlorous acids in multiple situations, including after the gym (pictured), over makeup and when my skin was breaking out. During this period, I paid attention to the following: Odour: Hypochlorous acid is related to chlorine and often smells similar, but the best formulas cleverly mask this swimming pool scent. Sensitivity: As a product designed to soothe irritated skin and benefit those with damaged skin barriers, I ensured all the formulas featured were gentle, no matter how frequently they were applied. Results: It can take a minimum of six weeks to see reliable results from a single product, which is why I used these sprays for months. I noted any differences in my skin and recorded any brands that stood out from an anti-inflammatory perspective. Value for money: Taking into account size, cost, packaging (including pump and spray dispensers) and ingredients, I weighed up which formulas had the most to offer. Why you can trust IndyBest reviews Lucy Smith has been reviewing beauty products for IndyBest since July 2024, covering everything from the best micellar waters to the best hyaluronic acid serums. When it comes to face mists, she's on top of the latest trends, and reviewed Rhode's glazing mist when it launched earlier this year. She's also experienced symptoms of rosacea on her face, so she was perfectly placed to assess the claims of these hypochlorous sprays. The best hypochlorous acid sprays for 2025 are:
Daily Mail
28 minutes ago
- Daily Mail
Mother-of-four, 43, reveals subtle mark she thought was just dry skin - but it was skin cancer: 'I ALWAYS wore sunscreen'
A mother-of-four who dismissed a small dry patch on her nose was shocked to be told it was skin cancer—because she had been 'obsessed' with wearing sun cream. Amanda Anderson, 43, first noticed the blemish in January but assumed it was down to the cold Utah winter. She visited her GP 'just to be on the safe side'—but was given a cream to soothe the dryness. But when the mark came back, bled and began to scab, Amanda's instincts told her something wasn't right. She went to another medic and a biopsy revealed basal cell carcinoma—the most common type of skin cancer. 'I wasn't super concerned at the beginning,' said Amanda, who lives in Layton and works for a suicide prevention charity. 'It was just a little dry spot on the side of my nose. With it being the winter it's common to have dry patches.' Doctors scheduled her for Mohs surgery, a specialist technique where thin layers of skin are removed and examined under a microscope until no cancer cells remain. Amanda needed three rounds before surgeons confirmed they had cleared it. The procedure left a penny-sized hole in her nose, which was repaired by folding skin from above and below to cover the gap. 'It's hard to hear,' Amanda said of her diagnosis. 'It's on my face and as a woman we do everything we can to make sure our faces look as good as possible. 'I'm obsessed about sun cream and shade. So it was a bit of a gut punch.' Amanda's father, Kirk Romney, 66, has faced his own battles with skin cancer and endured more than 17 Mohs surgeries to remove tumours from his face, neck and shoulders. But Amanda grew up in Arizona in the 1980s, when tanning was fashionable and sunscreen wasn't widely used. 'I'm very fair—I freckle, I don't tan easily,' she said. 'There was a tanning salon across the street from school that wasn't regulated. I lived in Arizona where it was year-round sun.' Now recovering, she is urging others to take skin protection seriously and to act quickly if they notice anything unusual. 'The damage is done when you're young,' Amanda said. 'I encourage my daughters to put sun cream on underneath their make-up. 'I'm trying to build healthy habits in my kids. People don't realise you can get sunburnt through the window of a car. 'We have to take care of our skin like you would your teeth. Skin cancer is so preventable.' Skin cancer is among the most common cancers in both the UK and the US. In Britain, melanoma—the deadliest form—affects around 17,000 people a year, while here are an estimated 156,000 new non-melanoma skin cancer cases annually, including basal cell and squamous cell carcinoma. In the US, around 9,500 people are diagnosed with skin cancer every single day. One in five Americans will develop it at some point in their lives. Basal cell carcinoma, which Amanda had, is rarely fatal but can cause significant damage if left untreated. It often appears on sun-exposed areas such as the nose, lips and ears—as the main trigger is UV exposure, from the sun. Squamous cell carcinoma is also common and can spread if not removed early. Melanoma, though accounting for just one per cent of cases, causes the vast majority of skin cancer deaths. Around 104,000 new melanomas are expected in the US this year, leading to more than 8,000 deaths. The good news is that survival is high when skin cancers are caught early. In the UK, more than nine in ten people with melanoma survive at least ten years—one of the highest survival rates of any cancer. But outcomes depend heavily on how early it is caught. If the disease has spread to the lymph nodes, survival falls to around 75 per cent, and if it reaches other organs just 35 per cent of patients live five years. Non-melanoma cancers like Amanda's are even more treatable, with cure rates above 95 per cent if removed promptly. Mohs surgery—considered the gold standard for high-risk or facial skin cancers—offers cure rates of up to 99 per cent. Experts urge people to be vigilant and check their skin regularly. For moles, dermatologists recommend the ABCDE rule: look out for Asymmetry, irregular Borders, Colour variation, large Diameter, and any Evolving change. Other red flags include sores that don't heal, patches that bleed or scab, and new lumps or bumps that look different to the rest. Amanda says her experience shows that anyone can be affected, no matter how careful they are. 'I had a gut feeling that it was going to need to be removed,' she said. 'I'm just glad I listened to my instincts.' She will now have check-ups every six months but doesn't need further treatment. Her advice is simple: don't ignore changes to your skin. 'Skin cancer is so preventable,' Amanda said. 'If you notice something unusual, don't wait. Get it checked.'
The Independent
an hour ago
- The Independent
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added.
